FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300825236> ?p ?o ?g. }

• W4300825236 endingPage "3356" @default.
• W4300825236 startingPage "3347" @default.
• W4300825236 abstract "Ramucirumab plus paclitaxel is considered the standard of care in the second-line treatment of gastric carcinoma (GC). The aim of this study was to evaluate plasma vascular endothelial growth factor-A (VEGF-A), VEGF-D, and circulating soluble VEGF receptor-2 (sVEGFR-2) as possible markers of resistance or response to ramucirumab administered with paclitaxel in pretreated metastatic GC patients. Plasma samples were collected at different time points (on days 1 and 15 of the first 3 cycles, at best radiologic response and at disease progression). VEGF-A, VEGF-D and sVEGFR-2 were analysed by ELISA. Correlations of biomarker baseline levels or dynamic changes with outcome measures were assessed. Progression-free survival (PFS) was the primary endpoint of the study. Forty-one patients were enrolled. VEGF-A and VEGF-D, but not sVEGFR-2, values significantly increased during treatment compared to baseline (P < 0.001). A positive correlation between VEGF-A and sVEGFR-2 at cycle 2 was found (P=0.045). At univariate analysis, higher baseline levels of VEGF-A were associated with worse OS (P=0.015). Early increase of sVEGFR-2 levels after the first treatment cycle was the only factor associated with longer PFS (6.6 vs. 3.6 months, P=0.049) and OS (18.6 vs. 5.2 months, P=0.008). Significance of sVEGFR-2 early increase was retained at multivariate analysis for OS (HR 0.32; 95% CI 0.12-0.91; P=0.032). The reported results confirmed the prognostic role of baseline VEGF-A and, with the limitations of the limited sample size and the lack of a control arm, suggested that the early increase of sVEGFR-2 after 1 cycle of treatment could be a potential predictive biomarker of benefit from second-line ramucirumab plus paclitaxel in GC." @default.
• W4300825236 created "2022-10-04" @default.
• W4300825236 creator A5008540924 @default.
• W4300825236 creator A5009272132 @default.
• W4300825236 creator A5011857824 @default.
• W4300825236 creator A5019141029 @default.
• W4300825236 creator A5025020524 @default.
• W4300825236 creator A5026345672 @default.
• W4300825236 creator A5036615333 @default.
• W4300825236 creator A5037539040 @default.
• W4300825236 creator A5039914248 @default.
• W4300825236 creator A5056137515 @default.
• W4300825236 creator A5058514609 @default.
• W4300825236 creator A5059511899 @default.
• W4300825236 creator A5064835475 @default.
• W4300825236 creator A5077975593 @default.
• W4300825236 creator A5082066847 @default.
• W4300825236 date "2022-01-01" @default.
• W4300825236 modified "2023-10-04" @default.
• W4300825236 title "Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer." @default.
• W4300825236 cites W1875373156 @default.
• W4300825236 cites W1967841898 @default.
• W4300825236 cites W1970730148 @default.
• W4300825236 cites W1978448859 @default.
• W4300825236 cites W1978833060 @default.
• W4300825236 cites W1993016882 @default.
• W4300825236 cites W2000292756 @default.
• W4300825236 cites W2011582582 @default.
• W4300825236 cites W2019607817 @default.
• W4300825236 cites W2038226684 @default.
• W4300825236 cites W2086773470 @default.
• W4300825236 cites W2102541302 @default.
• W4300825236 cites W2104759721 @default.
• W4300825236 cites W2106090525 @default.
• W4300825236 cites W2109491042 @default.
• W4300825236 cites W2111237964 @default.
• W4300825236 cites W2114012800 @default.
• W4300825236 cites W2134473118 @default.
• W4300825236 cites W2153297361 @default.
• W4300825236 cites W2168250718 @default.
• W4300825236 cites W2410546964 @default.
• W4300825236 cites W2519828822 @default.
• W4300825236 cites W2523443622 @default.
• W4300825236 cites W2568009005 @default.
• W4300825236 cites W2596924122 @default.
• W4300825236 cites W2762443719 @default.
• W4300825236 cites W2800353792 @default.
• W4300825236 cites W2884474039 @default.
• W4300825236 cites W3003788795 @default.
• W4300825236 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35968330" @default.
• W4300825236 hasPublicationYear "2022" @default.
• W4300825236 type Work @default.
• W4300825236 citedByCount "1" @default.
• W4300825236 countsByYear W43008252362023 @default.
• W4300825236 crossrefType "journal-article" @default.
• W4300825236 hasAuthorship W4300825236A5008540924 @default.
• W4300825236 hasAuthorship W4300825236A5009272132 @default.
• W4300825236 hasAuthorship W4300825236A5011857824 @default.
• W4300825236 hasAuthorship W4300825236A5019141029 @default.
• W4300825236 hasAuthorship W4300825236A5025020524 @default.
• W4300825236 hasAuthorship W4300825236A5026345672 @default.
• W4300825236 hasAuthorship W4300825236A5036615333 @default.
• W4300825236 hasAuthorship W4300825236A5037539040 @default.
• W4300825236 hasAuthorship W4300825236A5039914248 @default.
• W4300825236 hasAuthorship W4300825236A5056137515 @default.
• W4300825236 hasAuthorship W4300825236A5058514609 @default.
• W4300825236 hasAuthorship W4300825236A5059511899 @default.
• W4300825236 hasAuthorship W4300825236A5064835475 @default.
• W4300825236 hasAuthorship W4300825236A5077975593 @default.
• W4300825236 hasAuthorship W4300825236A5082066847 @default.
• W4300825236 hasConcept C121608353 @default.
• W4300825236 hasConcept C126322002 @default.
• W4300825236 hasConcept C143998085 @default.
• W4300825236 hasConcept C144301174 @default.
• W4300825236 hasConcept C167734588 @default.
• W4300825236 hasConcept C168563851 @default.
• W4300825236 hasConcept C203092338 @default.
• W4300825236 hasConcept C2777025900 @default.
• W4300825236 hasConcept C2777292972 @default.
• W4300825236 hasConcept C2779551604 @default.
• W4300825236 hasConcept C2780394083 @default.
• W4300825236 hasConcept C2781197716 @default.
• W4300825236 hasConcept C38180746 @default.
• W4300825236 hasConcept C55493867 @default.
• W4300825236 hasConcept C71924100 @default.
• W4300825236 hasConcept C86803240 @default.
• W4300825236 hasConcept C90924648 @default.
• W4300825236 hasConceptScore W4300825236C121608353 @default.
• W4300825236 hasConceptScore W4300825236C126322002 @default.
• W4300825236 hasConceptScore W4300825236C143998085 @default.
• W4300825236 hasConceptScore W4300825236C144301174 @default.
• W4300825236 hasConceptScore W4300825236C167734588 @default.
• W4300825236 hasConceptScore W4300825236C168563851 @default.
• W4300825236 hasConceptScore W4300825236C203092338 @default.
• W4300825236 hasConceptScore W4300825236C2777025900 @default.
• W4300825236 hasConceptScore W4300825236C2777292972 @default.
• W4300825236 hasConceptScore W4300825236C2779551604 @default.
• W4300825236 hasConceptScore W4300825236C2780394083 @default.

• next